KRAS was mutated in 88% and 74% of the tumor and blood samples, respectively, with high mutation abundance (MAF ≥ 30% and ≥ 5% in tumor and ctDNA samples, respectively) [31] observed in 35% and 37% of the samples. Here, KRAS is linked to neoplasm.